Fate Therapeutics Shares Plunge 52% On Terminated Collaboration with Janssen, Layoff Plans
Fate Therapeutics Shares Plunge 52% On Terminated Collaboration with Janssen, Layoff Plans...…
2,166€
7,92%
Echtzeit-Aktienkurs Fate Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Fate Therapeutics Inc. Aktie
Fate Therapeutics shares crater ~50% on ending tie-up with Janssen, layoffs
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization and…
Form 8-K FATE THERAPEUTICS INC For: Jan 03
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Strength Seen in Fate Therapeutics (FATE): Can Its 9.3% Jump Turn into More Strength?
Fate Therapeutics (FATE) saw its shares surge in the last session with trading volume being higher than average. The latest…
Fate Therapeutics hits 52-week low after preclinical data on leukemia treatment
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity…
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and…
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into…
Form 8-K FATE THERAPEUTICS INC For: Nov 07
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Fate Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE),…
Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 7.53% and 2.34%, respectively, for the quarter ended September 2022. Do…
Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for
Fate Therapeutics (FATE) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a…